Suppr超能文献

用于移植的肝细胞治疗与组织工程

Liver cell therapy and tissue engineering for transplantation.

作者信息

Vacanti Joseph P, Kulig Katherine M

机构信息

Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts; Department of Surgery, Massachusetts General Hospital, 55 Fruit St, WRN 1151, Boston, Massachusetts 02114; Department of Pediatric Surgery, MassGeneral Hospital for Children, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.

Center for Regenerative Medicine, Massachusetts General Hospital, Boston, Massachusetts; Department of Surgery, Massachusetts General Hospital, 55 Fruit St, WRN 1151, Boston, Massachusetts 02114; Department of Pediatric Surgery, MassGeneral Hospital for Children, Boston, Massachusetts.

出版信息

Semin Pediatr Surg. 2014 Jun;23(3):150-5. doi: 10.1053/j.sempedsurg.2014.05.001. Epub 2014 Jun 8.

Abstract

Liver transplantation remains the only definitive treatment for liver failure and is available to only a tiny fraction of patients with end-stage liver diseases. Major limitations for the procedure include donor organ shortage, high cost, high level of required expertise, and long-term consequences of immune suppression. Alternative cell-based liver therapies could potentially greatly expand the number of patients provided with effective treatment. Investigative research into augmenting or replacing liver function extends into three general strategies. Bioartificial livers (BALs) are extracorporeal devices that utilize cartridges of primary hepatocytes or cell lines to process patient plasma. Injection of liver cell suspensions aims to foster organ regeneration or provide a missing metabolic function arising from a genetic defect. Tissue engineering recreates the organ in vitro for subsequent implantation to augment or replace patient liver function. Translational models and clinical trials have highlighted both the immense challenges involved and some striking examples of success.

摘要

肝移植仍然是治疗肝衰竭的唯一确定性方法,并且仅适用于极少数终末期肝病患者。该手术的主要局限性包括供体器官短缺、成本高、所需专业知识水平高以及免疫抑制的长期后果。替代性的基于细胞的肝脏疗法可能会极大地扩大接受有效治疗的患者数量。关于增强或替代肝功能的研究分为三种一般策略。生物人工肝(BALs)是体外装置,利用原代肝细胞或细胞系的培养盒来处理患者血浆。注射肝细胞悬液旨在促进器官再生或提供因遗传缺陷而缺失的代谢功能。组织工程在体外重建器官以便随后植入,以增强或替代患者的肝功能。转化模型和临床试验既突出了所涉及的巨大挑战,也展示了一些显著的成功案例。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验